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The IGCCCG stage was III A in 1, III B in 3 and III C in 7. The med-
ian age was 24 years (range 17–33).
Results: Ten patients were assessable for response: 3 CR, 4 PR, 2
SD and 1 PD were observed. One patient died due to brain hemor-
rhage (on day 10 from Carbo-PEC). Four patients underwent to
surgery and two were pCRs. Six patients (54%) are still alive with
a median follow up of 100 months (range 78–148). Four patients
progressed after chemotherapy and died from disease at 5, 10,
32 and 34 months from the date of the start of the first chemo-
therapy cycle. Event free survival rates (defined as time to disease
progression, relapse or death, whatever the cause) were mea-
sured from the date of the start of the first chemotherapy cycle
at 1 and 3 years and resulted 72% and 54%, respectively.
Conclusions: Our experience showed that early intensification
HDCT is an effective and tolerable regimen in patients relapsing
after a standard first line chemotherapy. Further clinical trials of
HDCT should analyze predictive factors for treatment outcome.
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Background: Treatment of borderline ovarian tumours is based on
surgery while chemotherapy is poorly effective. Advance border line
ovarian tumours are rare nad response tochemotherapy ispoor. Bor-
der line cancer frequently express estrogen receptors and few cases
responding to hormonal treatments have been reported.
Methods: We describe three cases of recurrent serous disease out
of 42 newly diagnosed border line cancer observed at our institu-
tion in 5 years. In all three cases estrogen receptor was determined
by immunohistochemistry and was found positive. Patients were
treated with 20 mg/daily tamoxifen until progression.
Results: In no case we observed a complete remission, but in all
a clinical and serological Ca 125 response was observed. In one
patient a control was maintained for 3 years. In another, after
progression, a new response was obtained doubling tamoxifen
dose. Two of 3 patients are alive continuing tamoxifen and in
response from 10 and 15 months, respectively.
Conclusions: Our data support the hypothesis that hormonal
treatment represents an option for recurrent borderline ovarian
tumours.
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REDISCOVERING IMMUNOTHERAPY IN COMBINATION WITH
MOLECULARLY TARGETED AGENTS IN RENAL CELL CANCER
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Ducceschi, E. Ferrario. Istituto Nazionale Tumori, Milan, Italy
Renal cell carcinoma accounts for approximately 2–3% of all
malignancies and includes different histological subtypes.
Prognosis of metastatic disease (mRCC) still remains unfa-
vourable and patients survival depends on well known prognostic
factors, as defined by the MSKCC score. Overall, the median sur-
vival in advanced disease is about 14 months.
Cytokine-based immunotherapy with interferon-alfa (IFN-
alfa) and interleukin-2 (IL-2), alone or in association, is considered
the standard care for mRCC.
From 2005, in the targeted therapies era, some significant clin-
ical trials showed the promising activity and efficacy of new drugs
like Sorafenib, Sunitinib, Temsirolimus, Everolimus and Bev-
acizumab. These biomolecular agents have improved disease
control in patients with mRCC.
In particular, Sorafenib is an orally available multikinase
inhibitor that demonstrated, as single agent, an improvement of
progression-free survival in cytokine-refractory mRCC.
Some clinical trials explored the efficacy and safety of the
association between biomolecular agents such as Sorafenib itself,
Bevacizumab or Temsirolimus and immunotherapy with IFN-alfa
and IL-2.
The rationale of bio-immunotherapy of mRCC with targeted
agents in combination with cytokines is represented by their dif-
ferent mechanisms of action and possible synergistic effects in
blocking cancer growth.
The ROSORC trial is a phase II italian study of first line
therapy with Sorafenib plus low dose IL-2 administered subcu-
taneously versus Sorafenib alone in unresectable and/or meta-
static RCC. The accrual target is set at 128 patients and the
main endpoints are the progression-free survival, the overall sur-
vival, the response rate and the safety in both arms of therapy.
In our experience the association between cytokines and tar-
geted therapies is feasible and we purpose to choose this combi-
nation regimen in the upfront treatment of particular subgroups
of patients, according to risk stratification and objectives of
clinicians.
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IMAGE GUIDED RADIATION THERAPY (IGRT) IN THE TREAT-
MENT PLANNING OF PROSTATE CANCER: ACCURACY AND PRE-
CISION OF RADIATION THERAPY THROUGH MODERN IMAGING
TECNOLOGIES
M. Santoro, P. Petitto, D. Pingitore. Department of Onco-Hematology,
Hospital Pugliese-Ciaccio, Via Pio X, 88100 Catanzaro, Italy
The objective principal of the radiotherapy it is the control
local or locoregional to curative purpose with saving of the nor-
mal tissues. In the last decades the possibility to have available
software able to integrate diagnostic data coming from images of
Computerized Tomography (CT), of Magnetic Resonance Imag-
ing (MRI) and nuclear medicine (NM) with algorithms of calcula-
tion of doses able to calculate the dose in more dimensions have
allowed to realise the radiotherapy conformal (3D-CRT) to the
purpose to realise of radiant treatments more and more individ-
ualised and with smaller late effects.
Advances in the delivery of radiotherapy treatment such as
the 3D-CRT and Intensity Modulated Radiation Therapy (IMRT)
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